Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price

DSpace Repository

Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price

Author: Michaeli, Julia Caroline; Michaeli, Thomas; Trapani, Dario; Albers, Sebastian; Dannehl, Dominik; Wuerstlein, Rachel; Michaeli, Daniel Tobias
Tübinger Autor(en):
Dannehl, Dominik
Published in: Breast Cancer (2024), Bd. 31, H. 6, S. 1144-1155
Verlagsangabe: Tokyo : Springer
Language: English
Full text: http://dx.doi.org/10.1007/s12282-024-01634-x
ISSN: 1340-6868
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)